2025.10.15
TCROSS Co., Ltd. announced that the results of a study utilising its decision-support model InsighTCROSS for dyslipidaemia treatment were reported by Satoru Hashimoto et al. from TCROSS Co., Ltd./Graduate School of Strategic Management, Chuo University, in the Journal of Japanese Association for Health Care Administrators.
The study investigated the use of PCSK9 inhibitors—lipid-lowering agents whose utilisation is rapidly expanding in Japan—to identify which types of physicians are increasing their prescriptions and what factors influenced their prescribing behaviour. In today’s digital era, cardiologists, like all users, are exposed to a wide range of information, making it essential to capture unconscious behaviours and insights that drive medical decisions. Using InsighTCROSS, the research identified both the criteria behind physicians’ prescribing decisions and the specific physician segments that select certain medications.
Hashimoto S, et al. J Jpn Assoc Health Care Adm. 2025;19: 5-14
InsighTCROSS is a decision-support model developed by TCROSS Co., Ltd. for pharmaceutical and medical device companies. By integrating statistical analysis and data science with traditional sales and marketing practices, InsighTCROSS enables the visualisation of physicians’ prescribing behaviours and decision-making criteria. This approach supports more effective strategy development, allowing companies to optimise resource allocation and reduce marketing costs. Ultimately, InsighTCROSS contributes to more appropriate healthcare spending and the advancement of a sustainable healthcare system.